Check-Cap (NASDAQ:MBAI) Stock Price Down 3.2% – What’s Next?

Check-Cap Ltd (NASDAQ:MBAI) shares dropped 3.2% on Tuesday . The stock traded as low as $1.77 and last traded at $1.81. Approximately 78,665 shares changed hands during mid-day trading, a decline of 61% from the average daily volume of 204,279 shares. The stock had previously closed at $1.87.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Check-Cap in a research report on Friday, April 24th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, Check-Cap presently has a consensus rating of “Sell”.

Check-Cap Stock Up 1.6%

The firm has a market cap of $13.56 million, a price-to-earnings ratio of -0.67 and a beta of 0.57. The business has a 50-day moving average of $1.68.

About Check-Cap

Check-Cap Ltd. (NASDAQ: MBAI) is an Israel-based medical technology company focused on non-invasive screening solutions for colorectal cancer. The company develops an ingestible imaging capsule and associated detection system intended to provide a patient-friendly alternative to traditional colonoscopy and CT colonography for colorectal screening and polyp detection.

Check-Cap’s technology centers on a swallowable capsule that acquires images of the colon as it traverses the gastrointestinal tract; external detectors capture the transmitted signals and software reconstructs images for clinical review.